Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Year end trading update

19 Jan 2009 07:00

RNS Number : 8037L
Cello Group plc
19 January 2009
 



19 January 2009

  

Cello Group plc

Year end trading update

 

Cello Group plc ("Cello" or the "Group", AIM: CLL), the leading independent market research and consulting group, today provides the following trading update for the year ended 31 December 2008

 

Since the announcement of the Group's interim results in early September, trading has tightened across certain sectors of Cello's broad domestic and international client base As a result, the Board anticipates that the Group's results for the full year will be at the lower end of market expectations.

There has been very strong cash conversion in the second half of 2008, as a result of which the Board expects to report year end net debt of less than £10.5m, significantly below consensus expectations.

The Group has agreed enlarged banking facilities with the revolving credit facility now increased from £18.0m to £20.0m for 2009, amortising to £17.0m for 2010. The overdraft facility of £2.0m has also been renewed and is now a multi-currency arrangement. The extra interest cost associated with these changes is expected to be broadly offset by lower overall interest rates.

The Group has re-estimated its total anticipated earn out obligations. These are now expected to be £15.2m compared with a previous estimate of £19.2m, with a minimum loan note component of £6.3m and the balance of £8.9m payable in shares. £7.8m of this total is anticipated to be settled in May 2009 with £3.2m payable in loan notes and £4.6m payable in shares. The balance of the total earn out commitment is payable between 2010 and 2013, with a loan note payment of £0.6m expected to be paid in 2010. The Group is entitled to pay an increased proportion of these total obligations in loan notes.

As well as the strong operating cash position and the reduced earn out provisions, the Group has continued to prudently reduce its cost base. In total over £2.0m of staff costs, on an annualised basis, have been removed during 2008.

Allan Rich, whose appointment as Acting Non-Executive Chairman was announced on September 2008has been confirmed as Non-Executive Chairman. Allan brings with him a wealth of experience of managing successfully through economic downturns.

 

The Group remains realistically cautious about the current outlook. While it is too early to give detailed guidance, numerous clients have indicated their intention to maintain their expenditure levels and the Group is seeing refreshed levels of spend from several of its public sector clients. In addition, all of Cello's investment start-up businesses are now trading profitably. All these factors, including the Group's strong financial position, should hold the Group in good stead in the current economic environment.

 

Cello expects to announce its preliminary results for the year ended 31 December 2008 on Tuesday 17 March 2009.

 

Enquiries

 

Cello Group 

 

Mark ScottChief Executive

020 7812 8460

Mark Bentley, Finance Director

 

Singer Capital Markets

 

Nicholas How

020 3205 7620

 

 

College Hill

 

Adrian Duffield/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.co.uk)

 

Cello is a market research and consulting group that listed on AIM in November 2004.

 

The Group's strategy is to create value for shareholders by building a world class market research business and a leading direct response business.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUUACGUPBGAQ
Date   Source Headline
17th Mar 20097:00 amRNSFinal Results
26th Feb 20098:00 amRNSNotice of Results
19th Jan 20097:00 amRNSYear end trading update
18th Dec 200812:38 pmRNSKevin Steeds
4th Dec 20087:00 amRNSDirector/PDMR Shareholding
30th Oct 20081:33 pmRNSChange of Adviser Name
16th Sep 20087:00 amRNSInterim Results
2nd Sep 20082:00 pmRNSInterim Board role change
18th Aug 20084:12 pmRNSNotice of Results
18th Aug 20081:13 pmRNSHolding(s) in Company
13th Aug 20082:16 pmRNSHolding(s) in Company
6th Aug 20082:56 pmRNSHolding(s) in Company
4th Jul 20087:00 amRNSHalf year trading update
24th Jun 200810:44 amRNSDirector/PDMR Shareholding
12th Jun 20081:22 pmRNSDirector/PDMR Shareholding
20th May 20081:25 pmRNSAGM Statement
23rd Apr 200812:59 pmRNSAnnual Report & AGM
17th Apr 20087:00 amRNSAdditional Listing / TVR
28th Mar 20086:11 pmRNSAdditional listing / TVR
25th Mar 20084:04 pmRNSDirector/PDMR Shareholding
19th Mar 20088:35 amRNSDirector/PDMR Shareholding
18th Mar 200810:40 amRNSPerformance Share Option Plan
18th Mar 20087:01 amRNSFinal Results
26th Feb 20087:01 amRNSTotal Voting Rights
13th Feb 200811:03 amRNSNotice of Results
17th Jan 200810:53 amRNSTransaction in Own Shares
16th Jan 20083:03 pmRNSDirector/PDMR Shareholding
16th Jan 20082:19 pmRNSTransaction in Own Shares
16th Jan 200810:54 amRNSTransaction in Own Shares
15th Jan 20087:00 amRNSTrading Statement
3rd Jan 20084:56 pmRNSNotification of Interests
21st Dec 20078:05 amRNSChange of Adviser
14th Dec 200711:10 amRNSDirector/PDMR Shareholding
30th Nov 20073:29 pmRNSTotal Voting Rights
24th Oct 20071:30 pmRNSDirector/PDMR Shareholding
24th Oct 20077:00 amRNSPerformance Share Option Plan
23rd Oct 20077:01 amRNSAcquisition
2nd Oct 20079:59 amRNSTransactions in own shares
26th Sep 200711:35 amRNSAdditional Listing
17th Sep 20077:01 amRNSAcquisition
11th Sep 20077:01 amRNSInterim Results
31st Aug 20075:08 pmRNSTVR Update
30th Aug 20079:15 amRNSAdoption of IFRS
20th Aug 20072:53 pmRNSNotice of Results
13th Aug 20074:40 pmRNSRule 26
30th Jul 20071:55 pmRNSAdditional Listing
20th Jul 200710:00 amRNSHolding(s) in Company
12th Jul 20077:00 amRNSTrading Statement
9th Jul 20072:06 pmRNSTotal Voting Rights
6th Jul 20077:01 amRNSAcquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.